{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Glutathione",
    "short_name": "Glutathione",
    "aliases": [
      "gsh",
      "reduced glutathione",
      "l-glutathione",
      "l glutathione"
    ],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Classification describes what Glutathione is and the general domain where it appears."
    },
    "status": {
      "category": "otc_supplement",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Status reflects how Glutathione appears in clinical literature and/or real-world contexts. This is descriptive only."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk scoring reflects evidence quality, adverse-signal plausibility, and uncertainty. Limited data increases uncertainty.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Glutathione is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a bioactive compound discussed in research and/or clinical contexts",
        "this entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Glutathione",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "needs_prescription": false,
    "meta": {
      "priority": "normal",
      "notes_seed": "Antioxidant tripeptide (GSH) widely used as supplement/adjunct; evidence varies by route/formulation; avoid protocol claims."
    },
    "topics": {
      "primary": [
        "topic_skin_cosmetic",
        "topic_longevity_aging"
      ]
    },
    "slug": "glutathione"
  },
  "canonical_name": "Glutathione",
  "interactions": {
    "drug_classes": [],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "Glutathione is discussed for antioxidant and skin-brightening themes. Oral and topical use are common; injectable use is higher-risk largely due to sourcing/quality and allergy risk, and outcomes vary widely.",
    "benefits": [
      "antioxidant and oxidative stress discussions (outcomes variable)",
      "skin tone/brightening claims are common (evidence mixed and often overstated)",
      "sometimes discussed for liver support themes (context-dependent)"
    ],
    "side_effects_common": [
      "nausea or stomach upset",
      "headache",
      "skin rash or itching"
    ],
    "side_effects_serious": [
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)",
      "wheezing or severe bronchospasm symptoms in susceptible people",
      "severe rash or swelling that escalates quickly"
    ],
    "who_should_be_cautious": [
      "people with asthma or airway reactivity",
      "people with multiple medication allergies or prior anaphylaxis",
      "pregnant or breastfeeding individuals",
      "adolescents (cosmetic-driven use with limited long-term data)"
    ],
    "schema_version": "practical_block_v1"
  }
}
